Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion

Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon EGFR G719D/L861Q mutations and an acquired novel CUX1-MET fusion

Non-small cell lung cancer (NSCLC) patients harboring MET exon 14 skipping or high MET amplification display a high rate of response to MET inhibitors. However, MET fusions in NSCLC have rarely been revealed. In this report, a 63-year-old woman with lung adenocarcinoma (LADC), harboring EGFR exon 18...

Full description

Bibliographic Details
Main Authors: Lanzi Ou, Yicong Tang, Yanming Deng, Lijie Guo, Qingqing He, Tingting He, Weineng Feng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
lung adenocarcinoma
EGFR mutations
CUX1-MET fusion
icotinib plus crizotinib
partial response
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.911362/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.911362/full

Similar Items